Editor's Note The antibody shot Nirsevimab can protect infants from hospitalization from respiratory syncytial virus (RSV). The results from the new clinical trial were published December 28 in The New England Journal of Medicine. Affecting two of three children in their first year of life, RSV causes seasonal infection and,…
Editor's Note This study by investigators in the Framingham Heart Study—an ongoing, prospective cohort study evaluating cardiovascular disease risk factors—finds that systemic symptoms after COVID-19 vaccination were associated with greater antibody response than local only or no symptoms. A total of 928 of 3,200 Framingham Heart Study participants completed this…